News | Renal Denervation | April 24, 2013

Cardiosonic Begins Enrollment in the TIVUS I Renal Denervation Trial

April 24, 2013 — Cardiosonic Inc. announced the completion of the first phase of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and performance of the TIVUS System, a high intensity, non-focused therapeutic ultrasound catheter system for remote tissue ablation for the treatment of hypertension by renal denervation (RDN).

The study enrolled the first five patients at Royal Perth Hospital (RPH), Australia and patient screening is continuing. Sharad Shetty, M.D., principal investigator at RPH, completed the procedures with a 100 percent acute success rate in accessing the vessels and delivering therapy. "The performance of renal denervation with an advanced, ultrasonic catheter has been shown to be quick, easy and seems to be associated with minimal pain. The TIVUS System by Cardiosonic has great potential to become an important technology for management of resistant hypertensive patients," commented Shetty. Shetty will present interim results from the FIM trial at the Euro PCR conference, Paris, May 21 to 24.

The company completed extensive bench and animal studies and following these initial human results is submitting its next human clinical trial to 20 sites worldwide. Krishna Rocha-Singh, an advisor to the company and a leader in the rapidly growing field of RDN, from the Prairie Heart Institute at the St. John’s Hospital in Springfield, Ill., commented that, “The TIVUS system has great potential to improve the process and outcomes of RDN procedures. In addition the TIVUS system may expand the population of patients eligible for RDN therapy by obviating current anatomic and physiologic restrictions and contra-indications."

Benny Dilmoney, Cardiosonic CEO, commented that, "We are enthusiastic about completing the first phase of enrollment and progressing towards completion of our FIM patients recruitment and follow-up. Cardiosonic has completed the development of our second generation multi-directional catheter and initiated submission for its study at 20 centers worldwide. We believe that this advanced catheter design will further improve RDN procedures."

Related Content

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries.

Feature | Hypertension | May 16, 2021 | By Dave Fornell, Editor
May 16, 2021 — Two months after undergoing...
Childhood Obesity and High Blood Pressure Warn of Future Heart Disease. Vivian Fornell playing doctor at the Elgin Public Library. Photo by Dave Fornell
News | Hypertension | April 30, 2020
April 30, 2020 — A large study in adolescents and children, some as young as 3 years of age, shows a link between obe
Aria CV Pulmonary Hypertension System_Aria CV PH System

The Aria CV Pulmonary Hypertension System.

News | Hypertension | February 27, 2020
February 27, 2020 — Aria CV Inc.
BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019
October 10.
Abnormal Blood Pressure in Middle And Late Life Influences Dementia Risk

Image courtesy of the American Heart Association

News | Hypertension | August 20, 2019
In a study that spanned two and a half decades and looked at data from more than 4,700 participants, Johns Hopkins...
Blood Pressure Control Less Likely Among Those Treated in Low-income Areas
News | Hypertension | August 14, 2019
People enrolled in a large clinical hypertension management trial were half as likely to control their blood pressure ...
Pediatricians Assess How to Personalize Hypertension Treatment in Children
News | Hypertension | July 29, 2019
High blood pressure among children is on the rise and a lack of research about how to treat it has left pediatricians...
BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction
News | Hypertension | June 04, 2019
Orchestra BioMed Inc. announced the presentation of two-year clinical data from the European Moderato I study of...